https://www.cambium.bio/ https://www.cambium.bio/investors https://www.cambium.bio/About-Us https://www.cambium.bio/Contact-Us https://www.cambium.bio/Privacy-Policy https://www.cambium.bio/expanded-access-policy https://www.cambium.bio/Terms-of-Service https://www.cambium.bio/Cookie-Policy https://www.cambium.bio/Investors-and-Media https://www.cambium.bio/Investors-and-Media/Events-and-Presentations https://www.cambium.bio/Investors-and-Media/News-Releases https://www.cambium.bio/Investors-and-Media/Financial-Information https://www.cambium.bio/Investors-and-Media/ASX-Announcements https://www.cambium.bio/Investors-and-Media/Corporate-Profile https://www.cambium.bio/Our-Pipeline https://www.cambium.bio/Our-Science https://www.cambium.bio/investors/quarterly-cashflow-report---period-ending-31-december-2025 https://www.cambium.bio/investors/cambium-bio-secures-a-2.4-million-strategic-investment-from-major-shareholder-zybt https://www.cambium.bio/investors/corporate-presentation https://www.cambium.bio/investors/quarterly-cashflow-report---period-ending-30-september-2025 https://www.cambium.bio/investors/annual-report-(june-2025) https://www.cambium.bio/investors/quarterly-cashflow-report-period-ending-30-june-2025 https://www.cambium.bio/investors/cambium-bio-raises-2-12m-via-fully-subscribed-placement https://www.cambium.bio/investors/cambium-bio-clears-fda-regulatory-hurdles-to-commence-phase-3-dosing-for-elate-ocular https://www.cambium.bio/investors/cambium-bio-receives-ethics-approvals https://www.cambium.bio/investors/quarterly-cashflow-report-business-update-march-2024 https://www.cambium.bio/investors/change-of-registry-address-notification https://www.cambium.bio/investors/notice-of-ceasing-to-be-a-substantial-holder-cmb https://www.cambium.bio/investors/cambium-bio-release-of-shares-from-escrow https://www.cambium.bio/investors/notice-of-change-of-interests-of-substantial-holder-cmb-18-mar-2025 https://www.cambium.bio/investors/fda-approves-cambium-bio-s-potency-assay-strategy-for-elate-ocular-phase-3-clincial-trials https://www.cambium.bio/investors/change-of-directors-interest-notice-12-mar-25 https://www.cambium.bio/investors/notification-regarding-unquoted-securities-12-mar-25 https://www.cambium.bio/investors/application-for-quotation-of-securities-12-mar-25 https://www.cambium.bio/investors/mr-chiu-director-appointment-and-appedix-3x https://www.cambium.bio/investors/2025-03-04-results-of-general-meeting https://www.cambium.bio/investors/2025-03-03-response-to-queries-re-appendices-3x-and-3z https://www.cambium.bio/investors/2025-02-28-update-proposed-issue-of-securities-cmb https://www.cambium.bio/investors/cambium-bio-limited-half-year-report-(december-2024) https://www.cambium.bio/investors/half-year-report-fy2025 https://www.cambium.bio/investors/fda-approves-elate-ocular-phase-3-clinical-trial-protocol https://www.cambium.bio/investors/application-for-quotation-of-securities-13-feb-2025 https://www.cambium.bio/investors/placement-shares-cleansing-notice-feb-2025 https://www.cambium.bio/investors/quarterly-cashflow-report-business-update-december-2024 https://www.cambium.bio/investors/notice-and-general-meeting-and-proxy-4-march-2025 https://www.cambium.bio/investors/application-for-quotation-of-securities-12-dec-2024 https://www.cambium.bio/investors/placement-shares-cleansing-notice-12-dec-2024 https://www.cambium.bio/investors/fda-grants-fast-track-designation https://www.cambium.bio/investors/proposed-issue-of-securities-cmb https://www.cambium.bio/investors/cambium-bio-successfully-closes-a-3-0m-financing-round https://www.cambium.bio/investors/agm-results-and-re-appointment-of-dr-bala https://www.cambium.bio/investors/cambium-ceo-agm-presentation https://www.cambium.bio/investors/appendix-3b-proposed-issue-of-securities https://www.cambium.bio/investors/cambium-bio-board-changes https://www.cambium.bio/investors/quarterly-cashflow-report-business-update-september-2024 https://www.cambium.bio/investors/notice-of-meeting-26-nov-2024 https://www.cambium.bio/investors/ceo-acquires-additional-shares-demonstrating-strong-confidence-in-the-company https://www.cambium.bio/investors/initial-director-s-interest-notice-chang https://www.cambium.bio/investors/cambium-bio-strengthens-leadership-with-two-key-appointments https://www.cambium.bio/investors/date-of-agm-2024 https://www.cambium.bio/investors/cambium-bio-limited-annual-report-fy2024 https://www.cambium.bio/investors/no-ceo-revised-engagement-agreement-terms https://www.cambium.bio/investors/appendix-4g-and-corporate-governance-statement https://www.cambium.bio/investors/cambium-4e-and-annual-report https://www.cambium.bio/investors/corporate-governance-statement https://www.cambium.bio/investors/quarterly-cashflow-report-business-update-jun2024 https://www.cambium.bio/investors/notice-of-change-of-interests-of-substantial-holder-treasure https://www.cambium.bio/investors/notice-of-change-of-interests-of-substantial-holder-apex https://www.cambium.bio/investors/notice-of-change-of-interests-of-substantial-holder-cmb https://www.cambium.bio/investors/chagne-of-directors-interest https://www.cambium.bio/investors/consolidation-completion https://www.cambium.bio/investors/appendix-3h-notification-of-cessation-of-securities https://www.cambium.bio/investors/change-in-substantial-holding-cyntec https://www.cambium.bio/investors/change-in-substantial-holding-treasure https://www.cambium.bio/investors/change-in-substantial-holding-apex https://www.cambium.bio/investors/becoming-a-substantial-holder-treasure https://www.cambium.bio/investors/becoming-a-substantial-holder-apex https://www.cambium.bio/investors/appendix-3y-sebastian-tseng https://www.cambium.bio/investors/placement-shares-cleansing-notice-tranche-2 https://www.cambium.bio/investors/application-for-quotation-of-securities-cmb https://www.cambium.bio/investors/results-of-general-meeting https://www.cambium.bio/investors/correction-to-notice-of-general-meeting https://www.cambium.bio/investors/appendix-3a-3-security-consolidation https://www.cambium.bio/investors/notice-of-share-consolidation https://www.cambium.bio/investors/letter-to-shareholder-general-meeting https://www.cambium.bio/investors/notice-of-meeting-proxy https://www.cambium.bio/investors/becoming-a-substantial-holder-cyntec https://www.cambium.bio/investors/becoming-a-substantial-holder-zybt https://www.cambium.bio/investors/response-to-asx-aware-query https://www.cambium.bio/investors/quarterly-cashflow-report-and-business-update-period-ending-31-march-2024 https://www.cambium.bio/investors/meet-cambium-bio-team-at-bio-international-convention-in-san-diego https://www.cambium.bio/investors/notice-of-change-of-interests-of-substantial-holder https://www.cambium.bio/investors/director-s-appointment-dr-tseng https://www.cambium.bio/investors/initial-director-s-interest-notice-tseng https://www.cambium.bio/investors/placement-shares-cleansing-notice https://www.cambium.bio/investors/application-for-quotation-of-securities-(10-april-2024) https://www.cambium.bio/investors/proposed-issue-of-securities https://www.cambium.bio/investors/change-of-company-name-and-asx-code https://www.cambium.bio/investors/ceasing-to-be-a-substantial-holder-vesey https://www.cambium.bio/investors/ceasing-to-be-a-substantial-holder-lee https://www.cambium.bio/investors/ceasing-to-be-a-substantial-holder-kirman-2 https://www.cambium.bio/investors/regeneus-trebles-on-back-of-merger-deal-(sydney-morning-herald) https://www.cambium.bio/investors/resignation-of-non-executive-director-lee https://www.cambium.bio/investors/consideration-shares-cleansing-notice https://www.cambium.bio/investors/notice-of-initial-substantial-holder https://www.cambium.bio/investors/application-for-quotation-of-securities https://www.cambium.bio/investors/final-director-s-interest-notice-lee https://www.cambium.bio/investors/initial-director-s-notice-walts https://www.cambium.bio/investors/initial-director-s-interest-notice-waller https://www.cambium.bio/investors/cambium-bio-to-enter-asx-through-backdoor-listing-via-merger-with-regeneus-to-treat-dry-eye-disease https://www.cambium.bio/investors/cambium-bio-limited-half-year-report https://www.cambium.bio/investors/cambium-bio-limited-annual-report https://www.cambium.bio/investors/process-for-evaluating-board-and-executive-performance https://www.cambium.bio/investors/whistleblower-policy https://www.cambium.bio/investors/securities-trading-policy https://www.cambium.bio/investors/shareholder-communication-policy https://www.cambium.bio/investors/continuous-disclosure-policy https://www.cambium.bio/investors/audit-and-risk-committee-charter https://www.cambium.bio/investors/anti-bribery-and-corruption-policy https://www.cambium.bio/investors/code-of-conduct https://www.cambium.bio/investors/statement-of-values https://www.cambium.bio/investors/board-skills-matrix https://www.cambium.bio/investors/remuneration-and-nominations-committee-charter https://www.cambium.bio/investors/diversity-policy https://www.cambium.bio/investors/board-charter https://www.cambium.bio/investors/240405-cambium-bio-raises-a-3-48-million-in-strategic-placement https://www.cambium.bio/investors/regeneus-completes-merger-with-cambium-medical-technologies-llc